VIRTUOZZO
5.10.2021 13:02:10 CEST | Business Wire | Press release
Virtuozzo , a high-efficiency virtualization and hyperconverged infrastructure software leader, today announced it has acquired the technology and business of Jelastic , a multi-cloud Platform-as-a-Service (PaaS) software company, following a 10-year partnership.
Bringing Jelastic’s platform and application management capabilities in-house completes Virtuozzo’s core technology stack, delivering a fully integrated solution that supports all relevant anything-as-a-service (XaaS) use cases—from shared hosting to VPS to cloud infrastructure, software-defined storage and application management and modernization.
Virtuozzo offers the first fully integrated, easy-to-use and cost-efficient cloud solution designed for Cloud Service Providers, Managed Service Providers, Hosting Service Providers and their small and medium-sized business (SMB) customers. Virtuozzo also helps service providers increase profitability by providing a comprehensive portfolio of services and management tools.
Many PaaS vendors focus on a single-purpose offering. Jelastic, however, offers a robust, multi-purpose solution that, via the acquisition, will position Virtuozzo as a strong player in the PaaS market and further strengthen Virtuozzo’s position overall in the rapidly growing cloud services space.
“Virtuozzo and Jelastic have been strong partners over the past 10 years because of our complementary technologies and products,” said Alex Fine, CEO of Virtuozzo. “Virtuozzo containers have been incorporated into Jelastic’s Platform-as-a-Service for virtualization since that solution’s inception. Together, our engineering teams have co-developed solutions to enable features required by the market throughout our partnership. And now, with Jelastic joining our team, Virtuozzo can offer a complete, enterprise-grade, turnkey cloud enablement platform with fully integrated orchestration and a single point of management.”
Service Providers Want Simplicity, Automation and Choice
Service providers demand simplification and automation in container and cloud management. Jelastic has been providing a proven production-ready platform to cover these needs for years. The acquisition enables tighter integration and seamless enhancements.
In addition, service providers require a wider set of products to offer to end users. “Freedom of choice” is the core mantra that runs throughout the Jelastic ecosystem. Customers can choose various solutions and services, different types of workloads and management through an automated orchestration.
“Our companies are completely aligned and deeply understand the challenges and opportunities in the service provider industry where Platform-as-a-Service enablement is the key in the process of SaaS-ification and digitalization of its customers,” said Jelastic CEO Ruslan Synytsky. “Our joint partners will benefit from this acquisition since together we become a one-stop shop for Anything-as-a-Service, making it easier to get whatever they need for their users. The joint forces will accelerate the innovation and product development cycles. Together we can raise the bar for the industry standards with the help of our unique technologies that solve real problems of the cloud users.”
Platform-as-a-Service Market Shows Strong Growth
In 2022, the PaaS market is estimated to be worth approximately $71 billion U.S. dollars based on Gartner research . Cloud services (such as PaaS) are anticipated to grow by a high margin at around 27%.
The increased adoption of PaaS among service providers is driven by the end-users’ demand for access to easy-to-manage, high performing and scalable solutions.
By acquiring Jelastic, Virtuozzo can help its service provider partners achieve high ROI by both attracting new end-users and retaining existing customers through enabling XaaS use cases, providing more advanced automation and simplifying their own DevOps processes.
Business as Usual
Business continues as usual, with Jelastic now operating as a division of Virtuozzo—underscoring the value in Jelastic’s brand and technologies. Ruslan Synytsky has been appointed to Chief Technology Officer of Virtuozzo.
Integration of Jelastic’s sales and marketing teams will expand Virtuozzo’s worldwide footprint and brand visibility; and integration of Jelastic’s engineering resources will enable Virtuozzo to accelerate its full stack offering and provide a richer experience across multiple cloud providers.
Terms of the transaction were not disclosed.
About Jelastic
Jelastic is a Multi-Cloud DevOps PaaS for ISVs, telcos, service providers and enterprises needing to speed up development, reduce cost of IT infrastructure, improve uptime and security. The platform automates creation, scaling, clustering and security updates of cloud-native and traditional applications. Jelastic has a unique pay-as-you-use pricing model and is available as public, private, hybrid and multi-cloud in more than 100 data centers worldwide. The platform supports Java, PHP, Ruby, Node.js, Python, .NET, Go environments, as well as Docker and Kubernetes clusters.
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 750 service providers worldwide. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005403/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom